Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Priya C Doss

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
ACS Omega|April 15, 2024
Deciphering the Impact of Rare Missense Variants in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer through Whole Exome Sequencing: A Computational ApproachAmbritha Balasundaram, George Priya C Doss
ACS Omega|November 29, 2023
Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung CancerAmbritha Balasundaram, George Priya C Doss
Frontiers in Molecular Biosciences|January 26, 2024
A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutationsAmbritha Balasundaram, George Priya C Doss
Journal of Biological Physics|April 11, 2026
Computational and umbrella sampling analysis of HER2 D769H and D769Y variants: mutation-specific structural alterations and drug interactions in breast cancerTamizhini Loganathan, George Priya C Doss
Molecular Biotechnology|October 16, 2024
Targeting PilA in Acinetobacter baumannii: A Computational Approach for Anti-Virulent Compound DiscoveryMohanraj Gopikrishnan, George Priya C Doss
Frontiers in Bioscience (Landmark Edition)|June 5, 2014
TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseasesGeorge Priya C Doss, Govindasamy Agoramoorthy, Chiranjib Chakraborty
Current Cancer Drug Targets|November 28, 2018
Inhibition of the ATPase Domain of Human Topoisomerase IIa on HepG2 Cells by 1, 2-benzenedicarboxylic Acid, Mono (2-ethylhexyl) Ester: Molecular Docking and Dynamics SimulationsJemimah Naine Selvakumar, Subathra Devi Chandrasekaran, George Priya C Doss, et al.
ACS Omega|June 17, 2024
Deciphering the miRNA-mRNA Interaction Landscape between Breast Cancer and Triple-Negative Breast Cancer: An Integrated Bioinformatics ApproachAmbritha Balasundaram, Tanisha Saurav Mitra, Iftikhar Aslam Tayubi, et al.
Frontiers in Bioscience (Landmark Edition)|June 11, 2013
Nanoparticles as 'smart' pharmaceutical deliveryChiranjib Chakraborty, Soumen Pal, George Priya C Doss, et al.
Scientific Reports|August 6, 2014
Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitorsGeorge Priya C Doss, B Rajith, Chiranjib Chakraborty, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
ACS Omega|April 15, 2024
Deciphering the Impact of Rare Missense Variants in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer through Whole Exome Sequencing: A Computational ApproachAmbritha Balasundaram, George Priya C Doss
ACS Omega|November 29, 2023
Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung CancerAmbritha Balasundaram, George Priya C Doss
Frontiers in Molecular Biosciences|January 26, 2024
A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutationsAmbritha Balasundaram, George Priya C Doss
Journal of Biological Physics|April 11, 2026
Computational and umbrella sampling analysis of HER2 D769H and D769Y variants: mutation-specific structural alterations and drug interactions in breast cancerTamizhini Loganathan, George Priya C Doss
Molecular Biotechnology|October 16, 2024
Targeting PilA in Acinetobacter baumannii: A Computational Approach for Anti-Virulent Compound DiscoveryMohanraj Gopikrishnan, George Priya C Doss
Frontiers in Bioscience (Landmark Edition)|June 5, 2014
TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseasesGeorge Priya C Doss, Govindasamy Agoramoorthy, Chiranjib Chakraborty
Current Cancer Drug Targets|November 28, 2018
Inhibition of the ATPase Domain of Human Topoisomerase IIa on HepG2 Cells by 1, 2-benzenedicarboxylic Acid, Mono (2-ethylhexyl) Ester: Molecular Docking and Dynamics SimulationsJemimah Naine Selvakumar, Subathra Devi Chandrasekaran, George Priya C Doss, et al.
ACS Omega|June 17, 2024
Deciphering the miRNA-mRNA Interaction Landscape between Breast Cancer and Triple-Negative Breast Cancer: An Integrated Bioinformatics ApproachAmbritha Balasundaram, Tanisha Saurav Mitra, Iftikhar Aslam Tayubi, et al.
Frontiers in Bioscience (Landmark Edition)|June 11, 2013
Nanoparticles as 'smart' pharmaceutical deliveryChiranjib Chakraborty, Soumen Pal, George Priya C Doss, et al.
Scientific Reports|August 6, 2014
Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitorsGeorge Priya C Doss, B Rajith, Chiranjib Chakraborty, et al.
Pageof 2